Corvus Pharmaceuticals Q2 2026 Earnings Report

Corvus Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.17
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Corvus Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Corvus Pharmaceuticals Announcement Details

• Quarter: Q2 2026
• Date: 8/6/2026
• Time: Before Market Opens
• Conference Call Date: Thursday, August 6, 2026
• Conference Call Time: 4:30PM ET

Corvus Pharmaceuticals (NASDAQ:CRVS) is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape. Among these programs is an adenosine A2A receptor antagonist and a CD73-targeting monoclonal antibody, each advancing through Phase 1 and Phase 2 clinical trials. Additionally, the company is developing an ITK inhibitor aimed at enhancing T-cell activation. These assets are being evaluated both as monotherapies and in combination with checkpoint inhibitors across a range of solid tumor indications.

The company conducts its clinical trials in multiple regions, with ongoing studies in the United States and Europe. Corvus collaborates with leading academic centers and oncology consortia to accelerate trial enrollment and leverage translational research insights. This global trial footprint supports the company’s strategy of generating robust clinical data and exploring combination regimens that may address high-unmet-need cancers such as non–small cell lung cancer, renal cell carcinoma and colorectal cancer.

Founded in 2006 and headquartered in Carlsbad, California, Corvus Pharmaceuticals leverages a leadership team with extensive experience in oncology drug development, regulatory affairs and commercial strategy. Since its inception, the company has built a proprietary discovery platform and advanced multiple compounds from concept through early-stage clinical testing. As a Nasdaq-listed entity (NASDAQ: CRVS), Corvus continues to prioritize innovation in cancer immunotherapy with the goal of delivering meaningful new treatment options to patients worldwide.